Showing 1 - 7 results of 7 for search 'Hartmut J Ehrlich', query time: 0.03s Refine Results
  1. 1
    The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages

    The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages by Karim Chebli, Laura Papon, Conception Paul, Aude Garcel, Noëlie Campos, Didier Scherrer, Hartmut J. Ehrlich, Michael Hahne, Jamal Tazi

    Published 2017-07-01
    Get full text
    Article
  2. 2
    H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model.

    H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. by M Keith Howard, Nicolas Sabarth, Helga Savidis-Dacho, Daniel Portsmouth, Otfried Kistner, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett

    Published 2011-01-01
    Get full text
    Article
  3. 3
    Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study

    Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phas... by Sofie Rutsaert, Jean-Marc Steens, Paul Gineste, Basiel Cole, Sam Kint, P. Noel Barrett, Jamal Tazi, Didier Scherrer, Hartmut J. Ehrlich, Linos Vandekerckhove

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity.

    Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. by Annett Hessel, Michael Schwendinger, Georg W Holzer, Klaus K Orlinger, Sogue Coulibaly, Helga Savidis-Dacho, Marie-Luise Zips, Brian A Crowe, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett, Falko G Falkner

    Published 2011-01-01
    Get full text
    Article
  5. 5
    ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

    ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial by Pedro Giavina-Bianchi, MD, PhD, Eric Cua, MD, Karine Risso, MD, Véronique Mondain, MD, Anaïs Vissian, MSc, Cécile Joie, MSc, Philippe Pouletty, MD, Paul Gineste, PharmD, Hartmut J. Ehrlich, MD, PhD, Jorge Kalil, MD, PhD

    Published 2023-11-01
    Get full text
    Article
  6. 6
    Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.

    Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide. by Alfred T Welzel, Angela D Williams, Helen P McWilliams-Koeppen, Luis Acero, Alfred Weber, Veronika Blinder, Alex Mably, Sebastian Bunk, Corinna Hermann, Michael A Farrell, Hartmut J Ehrlich, Hans P Schwarz, Dominic M Walsh, Alan Solomon, Brian O'Nuallain

    Published 2012-01-01
    Get full text
    Article
  7. 7
    A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.

    A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. by Otfried Kistner, Brian A Crowe, Walter Wodal, Astrid Kerschbaum, Helga Savidis-Dacho, Nicolas Sabarth, Falko G Falkner, Ines Mayerhofer, Wolfgang Mundt, Manfred Reiter, Leopold Grillberger, Christa Tauer, Michael Graninger, Alois Sachslehner, Michael Schwendinger, Peter Brühl, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett

    Published 2010-02-01
    Get full text
    Article

Search Tools: